 |
|
 |
GILD Dividend History & Description — Gilead Sciences Inc
Gilead Sciences is a biopharmaceutical company, focusing on medicines to prevent and treat diseases, including HIV, viral hepatitis and cancer. Co.'s products include: Biktarvy®, which is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), an injection for intravenous use, which is a nucleotide analog RNA polymerase inhibitor indicated for certain patients for the treatment of COVID-19 requiring hospitalization; and Epclusa®, which is an oral formulation of a once-daily single tablet regimen of sofosbuvir and velpatasvir for the treatment of chronic hepatitis C virus (HCV) infection in adults and certain pediatric patients. When considering the Gilead Sciences Inc stock dividend history, we have taken known splits into account, such that the GILD dividend history is presented on a split-adjusted ("apples to apples") basis. Gilead Sciences Inc dividend history is presented both in graphical/chart form, and as a GILD dividend history data table along the right-hand column.

Name: |
Gilead Sciences Inc |
Stock buyback: |
GILD buyback |
Website: |
www.gilead.com |
Sector: |
Biotechnology |
Number of ETFs Holding GILD: |
136 (see which ones) |
Total Market Value Held by ETFs: |
$14,824,146,236.42 |
Total Market Capitalization: |
$96,158,000,000 |
% of Market Cap. Held by ETFs: |
15.42% |
|
GILD Stock Dividend HistoryThe GILD dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable GILD historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the GILD dividend history record. Also see the GILD stock dividend history data table along the right-hand column below.
 |
 |
|
 |
 Buy (3.00 out of 4)
34th percentile
 |
|
 |